Chronic Kidney Disease & Nutrition

Citation model. Claims grounded in AllNutrition's trust-scored library carry an inline bracketed reference [n] linking to the References section, which lists each source's evidence level and AllNutrition trust score (0–1). Where an AllNutrition query returned an overall evidence_strength and consensus_level, those labels are surfaced in the Evidence Review so readers can calibrate confidence. Only sources actually returned by the tool are cited; no trust scores are invented.

---

1. Introduction

Nutrition therapy in chronic kidney disease (CKD) is unusual among the diseases in this curriculum because the correct dietary advice inverts itself as the disease progresses. A patient counseled to restrict protein in CKD stage 3 may be told, within months of starting dialysis, to nearly double that same intake. A patient warned for years to avoid "high-potassium" fruits and vegetables may now be told that whole-plant potassium is largely irrelevant to their serum level, while the potassium hiding in a deli-meat additive is not. A patient told to limit dietary calcium to prevent kidney stones may in fact be raising their stone risk by doing so. This is a domain where outdated heuristics persist in clinical culture long after the evidence has moved past them, and where stage- and dialysis-status-specific nuance is not a footnote but the entire clinical skill.

CKD nutrition also sits at the intersection of several physiological axes covered elsewhere in this curriculum — acid-base balance, mineral metabolism, protein turnover, and cardiovascular risk — making it an ideal capstone for Unit IV. This module builds a framework organized around the central organizing question a clinician must ask at every visit: what stage of kidney disease, and is the patient on dialysis? Nearly every subsequent recommendation branches from that single fork.

2. Learning Objectives

By the end of this module, the learner will be able to:

1. Explain the evidence for dietary protein restriction in non-dialysis CKD, including the nuance of the MDRD trial, and contrast it with the substantially higher protein needs of dialysis patients (the protein-energy wasting paradox).
2. Describe modern, bioavailability-informed approaches to sodium, potassium, and phosphorus management, including why "avoid all high-potassium plants" is an outdated heuristic and where salt-substitute caution applies.
3. Explain the pathophysiology linking hyperphosphatemia and metabolic acidosis to CKD-mineral and bone disorder (CKD-MBD) and vascular calcification, and the evidentiary difference between phosphate-binder classes.
4. Evaluate the evidence for plant-dominant and base-producing (fruit/vegetable) dietary patterns in slowing CKD progression and correcting metabolic acidosis.
5. Apply nuanced, evidence-based dietary counseling for calcium-oxalate nephrolithiasis, including the calcium paradox.
6. Recognize protein-energy wasting (PEW) as a distinct, mortality-linked syndrome in dialysis patients and describe its assessment and management.
7. Tailor dietary counseling to CKD stage and dialysis status, and identify when protein or electrolyte restriction should be relaxed or avoided.

3. Scientific Foundations

3.1 Nephron physiology and the rationale for dietary intervention

As nephron mass declines in CKD, surviving nephrons undergo compensatory hyperfiltration — increased single-nephron glomerular filtration driven by afferent arteriolar dilation and elevated intraglomerular pressure. This adaptive response is also maladaptive: chronically elevated intraglomerular pressure accelerates glomerulosclerosis and proteinuria. High dietary protein and high dietary sodium each independently promote glomerular hyperfiltration and intraglomerular pressure, giving a direct mechanistic rationale for restricting both [1][2]. Sodium restriction lowers systemic and glomerular capillary pressure, reduces albuminuria by roughly 36% in trial data, and potentiates the antiproteinuric effect of ACE inhibitors and ARBs [10]. As filtration falls further, the kidney's capacity to excrete potassium, phosphate, and titratable acid is progressively lost, producing the uremic milieu: accumulation of nitrogenous waste, gut-derived uremic toxins (indoxyl sulfate, p-cresyl sulfate), phosphate retention, and chronic metabolic acidosis [1][5].

3.2 The uremic milieu, protein metabolism, and the MDRD nuance

Dietary protein restriction is the oldest and most contested lever in CKD nutrition, dating to the 1930s [3]. The landmark Modification of Diet in Renal Disease (MDRD) trial found no statistically significant difference in glomerular filtration rate (GFR) decline over 36 months between a low-protein diet (0.58 g/kg/day) and a usual-protein diet (1.3 g/kg/day) — but this headline result obscures an important nuance: the low-protein group showed an initial steeper GFR drop attributable to a hemodynamic (afferent arteriolar) effect rather than true disease progression, after which its rate of decline slowed relative to the usual-protein group [1]. Subsequent meta-analyses and observational cohorts have found that a 0.6 g/kg/day diet may delay dialysis initiation by up to 24 months in stage 4 CKD relative to an unrestricted diet [1][3].

Very-low-protein diets supplemented with ketoanalogues (VLPD+KA) — typically 0.3–0.4 g/kg/day protein plus keto-acid analogues of essential amino acids (roughly one tablet per 5 kg body weight, taken with meals) — extend this benefit further. Meta-analyses of RCTs show reduced dialysis initiation and lower mortality with this approach, and mechanistic studies demonstrate reduced glomerular hyperfiltration, lower indoxyl sulfate and p-cresyl sulfate, and improved endothelial function, with one prospective study reporting 95% arteriovenous fistula maturation success in VLPD+KA patients transitioning toward dialysis [4][10]. KDOQI (2020) gives VLPD a strong (1A) recommendation; the 2024 KDIGO guideline is more conservative (2C), reserving it for highly motivated, metabolically stable patients and otherwise recommending a "normalized" 0.8 g/kg/day for most adults with CKD stages 3–5 [1][2][3]. This KDOQI/KDIGO divergence, built from overlapping evidence, is a genuine, unresolved controversy in the field [3].

3.3 The protein-energy wasting paradox: pre-dialysis versus dialysis

The single most important stage-dependent reversal in this module is protein prescribing. In non-dialysis CKD, protein is restricted to reduce nitrogenous waste and intraglomerular pressure. Once dialysis begins, the calculus flips entirely: hemodialysis removes 6–12 g of free amino acids per 4-hour session (up to 15–17 g with high-efficiency hemodiafiltration), and peritoneal dialysis continuously loses plasma protein and amino acids into the dialysate [6]. Combined with dialysis-induced hypercatabolism and chronic inflammation, this drives protein-energy wasting (PEW) unless intake rises substantially. Recommended targets shift to approximately 1.2 g/kg/day for maintenance hemodialysis and 1.2–1.5 g/kg/day for peritoneal dialysis, with intakes below 0.73 g/kg/day in PD patients associated with reduced survival [6]. This is the protein-energy wasting paradox: the same nutrient that is restricted to protect pre-dialysis kidneys becomes protective against malnutrition and mortality once native kidney function is replaced by dialysis [6][8].

3.4 Mineral-bone axis: phosphorus, CKD-MBD, and acid-base physiology

Phosphorus retention is a central driver of CKD-mineral and bone disorder (CKD-MBD). Hyperphosphatemia promotes osteogenic transdifferentiation of vascular smooth muscle cells, dysregulates the Klotho/FGF23 axis, and drives secondary hyperparathyroidism, together accelerating vascular calcification, arterial stiffening, and bone disease [16][17]. Bioavailability, not just total content, now governs dietary guidance: inorganic phosphate additives (processed foods, "phos"-labeled ingredients) are 90–100% absorbed; animal-source organic phosphorus is 40–60% absorbed; plant-source phosphorus, largely bound as phytate that humans cannot hydrolyze, is under 40–50% absorbed [11][19]. The same bioavailability gradient applies to potassium — roughly 50–60% absorption from whole plant foods versus 70–90% from animal sources and 90–100% from additives and salt substitutes — which has driven a significant reappraisal of "avoid high-potassium produce" advice [11][15].

Metabolic acidosis compounds this picture. As acid excretion capacity falls, the body buffers acid by mobilizing bone mineral and catabolizing muscle protein, worsening both CKD-MBD and sarcopenia, while chronic acidosis independently promotes glomerular hyperfiltration [20][21]. Diets rich in fruits and vegetables supply organic anions (citrate, malate) that are metabolized to bicarbonate, reducing net acid excretion by roughly one-third — an effect comparable in some data to 0.5 mEq/kg/day of oral sodium bicarbonate [21]. Plant proteins, containing fewer sulfur-amino acids than animal protein, independently lower dietary acid load (potential renal acid load, PRAL; net endogenous acid production, NEAP) [22].

4. Clinical Relevance

CKD affects roughly one in seven adults globally and its nutritional management touches nearly every organ system covered in this curriculum: cardiovascular risk (sodium, phosphorus-driven vascular calcification), bone health (CKD-MBD), and metabolic status (protein-energy wasting, acidosis). Because dietary guidance reverses direction across the CKD-to-dialysis continuum and differs further by diabetes status, frailty, and stone history, generic "renal diet" handouts routinely mis-serve individual patients. A physician who can correctly stage a patient and apply the right lever — protein restriction versus repletion, plant-forward potassium liberalization versus additive avoidance, alkali therapy versus acid-load reduction — prevents both under-treatment (progression to dialysis) and iatrogenic harm (malnutrition, hyperkalemia from the wrong sources, calcium-restriction-driven stone recurrence).

5. Evidence Review

Established (high confidence):

• Dialysis (hemodialysis and peritoneal) substantially increases protein requirements (~1.2–1.5 g/kg/day) relative to non-dialysis CKD (~0.6–0.8 g/kg/day), owing to procedural amino acid losses and hypercatabolism — the protein-energy wasting paradox. evidence_strength: strong, consensus_level: moderate [6][8].
• Sodium restriction lowers blood pressure and albuminuria/proteinuria in CKD and potentiates RAAS-blocker efficacy. evidence_strength: strong, consensus_level: moderate [10][12].
• Phosphorus bioavailability differs sharply by source — additives (90–100%) > animal (40–60%) > plant (20–50%, phytate-bound) — reframing phosphorus counseling around food source rather than total content alone. evidence_strength: strong, consensus_level: moderate [11][19].
• Hyperphosphatemia and metabolic acidosis are mechanistically central to CKD-mineral and bone disorder and vascular calcification. evidence_strength: strong, consensus_level: moderate [16][17].
• Protein-energy wasting is common in dialysis patients (~28–56% depending on assessment tool) and is independently associated with mortality, hospitalization, and frailty. evidence_strength: strong, consensus_level: moderate [7][8].

Probable:

• Very-low-protein diets supplemented with ketoanalogues delay dialysis initiation and reduce uremic toxin burden in motivated, metabolically stable pre-dialysis patients, though KDOQI and KDIGO differ on the strength of this recommendation. evidence_strength: strong, consensus_level: moderate [1][2][3][4].
• Plant-dominant, high-diversity diets reduce dietary acid load (PRAL reductions of up to ~47% reported), raise serum bicarbonate, and are not associated with clinically meaningful hyperkalemia in stable non-dialysis CKD when whole-food, non-additive sources predominate. evidence_strength: strong, consensus_level: moderate [13][15].
• Sevelamer (a non-calcium phosphate binder) is associated with reduced all-cause mortality relative to calcium-based binders, which raise cardiovascular calcification risk. evidence_strength: strong (network meta-analysis), consensus_level: moderate [18].
• Restricting dietary calcium to prevent calcium-oxalate stones is counterproductive; normal-to-high dietary calcium (taken with oxalate-containing foods) binds intestinal oxalate and roughly halves stone recurrence risk relative to calcium restriction. evidence_strength: moderate, consensus_level: mixed [23][24].

Emerging:

• The plant-dominant low-protein diet (PLADO: 0.6–0.8 g/kg/day, ≥50% plant protein, high fiber, low sodium) as a unifying strategy addressing protein load, acid-base status, phosphorus bioavailability, and gut-derived uremic toxins simultaneously; ongoing RCTs are still defining its comparative effectiveness against standard dietetic counseling. evidence_strength: strong, consensus_level: moderate [9][13][14].
• Dietary acid load (PRAL/NEAP) as a modifiable, quantifiable risk factor for both kidney stones and CKD-associated bone/muscle catabolism. evidence_strength: moderate, consensus_level: mixed [22][25].

Controversial:

• The appropriate default protein target for stable, non-dialysis CKD stages 3–5: KDOQI 2020 supports low/very-low protein (0.55–0.6, or 0.3–0.4 g/kg/day with supplementation) as first-line, while KDIGO 2024 defaults to a more liberal 0.8 g/kg/day for most patients, reserving stricter restriction for high-risk, motivated individuals — a genuine, guideline-level disagreement built on similar underlying evidence. evidence_strength: moderate, consensus_level: mixed [1][2][3].
• Whether potassium-containing salt substitutes are safe in CKD: they are an efficient sodium-reduction and blood-pressure tool in the general population, but their near-complete (90–100%) potassium bioavailability makes them a distinct hyperkalemia hazard in patients with reduced renal potassium excretion, particularly on RAAS inhibitors or potassium-sparing diuretics; this module was unable to retrieve a CKD-specific trial via AllNutrition (query timed out twice) and flags this as an evidence gap requiring independent verification before clinical counseling [11].

Unsupported / overstated:

• The blanket instruction to avoid all high-potassium fruits and vegetables in CKD. Whole-plant potassium is only 50–60% bioavailable, correlates poorly with serum potassium, and restricting these foods forfeits their fiber, alkali, and cardiovascular benefits; the actual driver of most diet-related hyperkalemia is additive/processed-food potassium, not produce [11][14][15].

6. Practical Clinical Applications

Non-dialysis CKD (stages 3–5), stable, non-diabetic: Protein 0.6–0.8 g/kg/day (KDOQI favors the lower end with supervision; KDIGO defaults to 0.8), prioritizing plant and fish protein over red/processed meat [1][2][3]. Sodium <2–2.3 g/day [2][10]. Phosphorus <800–1000 mg/day, counseling focused on additive avoidance rather than blanket protein-food restriction, since protein sources also carry phosphorus [6][19]. Potassium individualized by serum level and eGFR, liberalizing whole-plant sources while restricting processed/additive sources and salt substitutes [11][14]. Consider fruit/vegetable-based alkali therapy or plant-dominant patterns for metabolic acidosis before or alongside oral bicarbonate [13][21].

Non-dialysis CKD, diabetic (diabetic kidney disease): Similar protein targets (~0.8 g/kg/day, avoid >1.3 g/kg/day), with stronger emphasis on plant protein for its independent insulin-sensitizing effect and combination with SGLT2 inhibitors, which appears synergistic with low-protein diets for reducing albuminuria [2][26].

Elderly/frail CKD: Relax protein restriction toward 1.0–1.2 g/kg/day when sarcopenia or frailty risk outweighs the benefit of slowing progression; VLPD is discouraged in metabolically unstable, malnourished, or frail patients [1][27][28].

Dialysis (hemodialysis/peritoneal): Protein 1.2–1.5 g/kg/day (higher, up to 1.4–2.0 g/kg/day, in catabolic states or established PEW); do not restrict protein to delay dialysis initiation once a patient is catabolic or malnourished [6][8]. Sodium remains restricted for interdialytic fluid control, but overly aggressive restriction risks intradialytic hypotension [10]. Phosphate binders are typically required; non-calcium binders (sevelamer) are favored where vascular calcification risk is high, taken with meals [18].

Nephrolithiasis (calcium-oxalate stones): High fluid intake (2–3 L urine output/day); normal-to-high dietary calcium taken with oxalate-containing meals (do not restrict calcium); limit concentrated oxalate sources (spinach, rhubarb, nuts — excess cashew intake has caused oxalate nephropathy); limit sodium and animal protein (both raise urinary calcium and lower citrate); favor citrus fluids over sugar-sweetened or high-fructose beverages [23][24][25].

When to avoid protein/electrolyte restriction: Active inflammation, catabolic illness, acute kidney injury, or established PEW — in these states protein needs rise (potentially to 2.0–2.5 g/kg/day on kidney replacement therapy) rather than fall [6][8]. Fluid restriction is not indicated in early-stage CKD (1–3) absent volume overload or heart failure; it becomes individualized to urine output and interdialytic weight gain (typically 500–1000 mL plus urine output) on dialysis.

Drug interactions: Phosphate binders must be taken with meals to bind dietary phosphorus in the gut; calcium-based binders risk hypercalcemia and accelerate vascular calcification; sevelamer additionally binds bile acids and fat-soluble vitamins, warranting monitoring [16][18]. RAAS inhibitor efficacy on albuminuria is enhanced by concurrent sodium restriction [10].

7. Clinical Pearls

• "What stage, and is the patient on dialysis?" is the single question that reverses most CKD dietary advice — protein above all.
• Potassium counseling should target the food's source, not its potassium content: a banana and a cola with potassium additives are not nutritionally equivalent hazards.
• Never restrict dietary calcium for stone prevention — it is one of the clearer paradoxes in clinical nutrition, and restriction increases oxalate absorption and stone risk.
• Phosphate binders only work if taken with the meal that contains the phosphorus; timing errors are a common, correctable cause of "refractory" hyperphosphatemia.
• A plant-forward diet in CKD is not merely permissible — it lowers acid load, bioavailable phosphorus and potassium, and uremic toxin generation simultaneously.

8. Common Misconceptions

• "All CKD patients should avoid fruits, vegetables, and legumes because of potassium." Modern bioavailability data show whole-plant potassium is poorly absorbed and often not the driver of hyperkalemia; blanket avoidance forfeits alkali and fiber benefits [11][14][15].
• "Protein restriction is always beneficial in kidney disease." True only pre-dialysis, and only for stable, non-catabolic patients; on dialysis, and in frailty or acute illness, the same restriction causes harm [6][8].
• "Dietary calcium should be minimized to prevent kidney stones." The opposite is closer to true for calcium-oxalate stones: adequate dietary calcium binds gut oxalate and lowers stone risk; it is oxalate, sodium, and animal protein excess that should be moderated [23][24].
• "A low-phosphorus diet just means eating less protein." Source and bioavailability matter more than gross protein-phosphorus co-occurrence; plant and mushroom protein sources carry substantially less absorbable phosphorus per gram than processed animal products [19][11].

9. Summary

CKD nutrition cannot be reduced to a single "renal diet." Protein prescribing inverts across the disease course — restricted pre-dialysis to lessen intraglomerular pressure and uremic toxin load, liberalized on dialysis to counter procedural losses and protein-energy wasting. Sodium restriction reliably lowers blood pressure and proteinuria across stages. Potassium and phosphorus management has shifted from blunt total-content restriction toward a bioavailability-informed approach that liberalizes whole plant foods while targeting processed additives and, with specific caution, potassium-based salt substitutes. Metabolic acidosis and CKD-mineral and bone disorder are mechanistically linked, and plant-dominant, base-producing dietary patterns address both while also lowering uremic toxin generation. In nephrolithiasis, the evidence directly contradicts old calcium-restriction dogma. Across every one of these domains, the decisive variable is not the nutrient in isolation but the patient's CKD stage, dialysis status, frailty, and comorbidity profile — precisely the individualized, stage-aware reasoning this module has built toward.

10. References

Ordered by evidence strength / relevance. Evidence level and AllNutrition trust score (0–1) as returned by the tool.

1. Low-protein diet for chronic kidney disease: Evidence, controversies, and practical guidelines. Journal of Internal Medicine (2025). Review — trust 0.74.
2. Nutritional Status Evaluation and Intervention in Chronic Kidney Disease Patients: Practical Approach. Nutrients (2025). Review — trust 0.742.
3. Dos and Don'ts in Kidney Nutrition: Practical Considerations of a Panel of Experts on Protein Restriction and Plant-Based Diets for Patients Living with Chronic Kidney Disease. Nutrients (2025). Observational — trust 0.708.
4. Effect of a Very-Low-Protein Diet Supplemented with Ketoacid Analogues on Arteriovenous Fistula Maturation and Endothelial Function. Nutrients (2026). Observational — trust 0.722.
5. Decreasing microbiota-derived uremic toxins to improve CKD outcomes. Clinical Kidney Journal (2022). Review — trust 0.713.
6. Food Frequency Questionnaire to Estimate Dietary Adherence in Hemodialysis Patients: A Pilot Study / Associations of dietary phosphorus-protein ratio, phosphorus-energy ratio, and protein-energy ratio with mortality in peritoneal dialysis patients. Nutrients (2025) trust 0.752; Frontiers in Nutrition (2026) — Observational, trust 0.8.
7. The burden of protein-energy wasting in children with CKD3-5D. Frontiers in Pediatrics (2026). Observational — trust 0.767.
8. Nutritional Strategies to Address Malnutrition in Dialyses Patients: A Systematic Review. Nutrients (2025). Systematic review — trust 0.857.
9. Plant-dominant low-protein diet versus standard care in adults with chronic kidney disease stages 3–5: A randomized controlled trial protocol. Nutrition Research (2026). RCT protocol — trust 0.802.
10. The Dietary Management Of Sodium In Children With Kidney Diseases — Clinical Practice Recommendations From The Pediatric Renal Nutrition Taskforce. Pediatric Nephrology (2025). Guideline — trust 0.907.
11. Traditional Brazilian dietary pattern as a factor associated with lower prevalence of dynapenic abdominal obesity in hemodialysis patients. BMC Nephrology (2026). Observational — trust 0.785.
12. Sodium Intake and Proteinuria/Albuminuria in the Population — Observational, Cross-Sectional Study. Nutrients (2021). Observational — trust 0.725.
13. High-Diversity Plant-Based Diet and Gut Microbiome, Plasma Metabolome, and Symptoms in Adults with CKD. Clinical Journal of the American Society of Nephrology (2025). RCT — trust 0.827.
14. Mind the Gut: Cognitive Decline, Microbiota, and Nutrition-Related Modulators in Older Adults with Chronic Kidney Disease. Nutrients (2026). Review — trust 0.738.
15. Novel Insights And Practical Strategies For Health Professionals To Improve The Uptake Of Plant-Based Diets In People With Chronic Kidney Disease. Kidney Research and Clinical Practice (2026). Review — trust 0.73.
16. The Effects Of Elevated Phosphate On The Kidney: Damaging The Gatekeeper. Pflügers Archiv — European Journal of Physiology (2026). Review — trust 0.765.
17. Research trends and emerging themes in abdominal aortic calcification: a 2005–2025 bibliometric analysis. Journal of Cardiothoracic Surgery (2026). Observational — trust 0.77.
18. Comparative Effectiveness and Safety of Phosphorus-Lowering Drugs for CKD 3-5 Stages. Kidney Medicine (2026). Systematic review (network meta-analysis) — trust 0.86.
19. Effects of Dietary Intervention on Nutritional Status in Elderly Individuals with Chronic Kidney Disease. Nutrients (2024). Observational — trust 0.727.
20. Association between food group intakes and metabolic acidosis in patients with non-dialysis-dependent chronic kidney disease. BMC Nephrology (2026). Observational — trust 0.6.
21. Prospective associations between the CKD-mineral bone disorder and metabolic acidosis. International Urology and Nephrology (2025). Observational — trust 0.65.
22. Rethinking protein choices: the association between the isocaloric substitution of dietary protein sources and dietary acid load in hemodialysis patients. BMC Nutrition (2026). Observational — trust 0.6.
23. The role of vegetarian diet in Nephrolithiasis. Quality in Sport (2024). Review — trust 0.762.
24. Associations between dietary macronutrient composition and kidney stone prevalence in the U.S. adult population. Urolithiasis (2026). Observational — trust 0.752.
25. Sweetened beverage intake and risk of incident kidney stone: results from the UK Biobank. Frontiers in Nutrition (2026). Observational — trust 0.762.
26. Gut microbiota-liver-kidney axis in diabetic kidney disease: mechanistic insights into amino acid metabolism and nutritional intervention strategies. Frontiers in Nutrition (2026). Review — trust 0.715.
27. Dietary intake patterns and nutritional adequacy in older adults with predialysis chronic kidney disease: a comparison by diabetes status. Clinical Nutrition Research (2026). Observational — trust 0.7.
28. ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clinical Nutrition (2021). Guideline — trust 0.828.

Supporting sources also surfaced: ESPEN practical guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease (Clinical Nutrition 2024, guideline, trust 0.89); Executive Summary of Evidence-Based Guidelines for the Diagnosis and Treatment of Pediatric CKD-MBD, Version 2024 (Kidney Int Rep 2026, guideline, trust 0.912); Mediterranean diet with high-phenolic EVOO slows kidney function decline and reduces inflammation in nondialysis CKD (Frontiers in Nutrition 2026, systematic review, trust 0.842); Impact of Plant-Based Diets on Blood Pressure in Chronic Kidney Disease: A Systematic Review and Meta-Analysis (J Ren Nutr 2025, systematic review, trust 0.765); New developments in epidemiological research on dietary patterns associated with chronic kidney disease (Frontiers in Nutrition 2026, review, trust 0.875); The Kidneys Went Nuts: Oxalate Nephropathy From Excessive Cashew Nut Consumption (Kidney Med. 2026, observational, trust 0.588); Dietary Acid Load and Kidney Stones: NEAP Shows a Positive Association in a Nationally Representative Sample (Food Science & Nutrition 2026, observational, trust 0.588); Effect of a home-based supervised personalised diet on malnutrition and frailty in dialysis patients: a randomised controlled trial (BMC Nutrition 2026, RCT, trust 0.832); Editorial: Advancements in nutritional management for patients with renal failure (Front. Med. 2026, review, trust 0.73).

Evidence gap note: A direct AllNutrition query on the safety of potassium-containing salt substitutes specifically in CKD populations timed out twice and could not be retrieved for this module; the discussion above is inferred from general potassium-bioavailability sources [11] and should be verified against a CKD-specific trial (e.g., SSaSS-type data in reduced-eGFR subgroups) before use in patient-facing materials.